Shared on 06 Aug 25
Fair value Increased 12%Enhanced Whole Genome Sequencing Will Open New Global Markets
Fulgent Genetics’ fair value has been revised upward, primarily reflecting improved consensus revenue growth forecasts and a higher future P/E multiple, with the analyst price target rising from $22.67 to $25.33. What's in the News Fulgent Genetics expects core revenue of approximately $320 million for full year 2025.
Shared on 01 May 25
Fair value Increased 11%Expanding Hereditary Testing And Digital Tools Will Transform Genomic Medicine
Shared on 24 Apr 25
Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 4.44%Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.